The FDA says Bell’s palsy was reported in four vaccine participants and none in the placebo group, out of the 44,000 total participants of the late-stage vaccine trial.
The US Food and Drug Administration (FDA) has recommended monitoring a possible outcome of facial paralysis, Bell’s palsy, after distribution of any of the vaccines in large populations.
The agency says although there is no clear basis upon which to conclude a causal relationship with vaccines
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
